ClinicalTrials.Veeva

Menu
V

Valley Clinical Trials, Inc | Northridge, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
LY3502970
Orforglipron
Metformin
Semaglutide
Sugar
Retatrutide
Insulin icodec
Empagliflozin

Parent organization

This site is a part of Valley Clinical Trials, Inc

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

35 of 84 total trials

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symp...

Enrolling
Coronavirus Disease (COVID-19)
Drug: Placebo
Drug: Molnupiravir
Locations recently updated

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Not yet enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Not yet enrolling
Hypertension
Overweight or Obesity
Drug: Placebo
Drug: Orforglipron

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Not yet enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compar...

Enrolling
Aortic Stenosis
Drug: Matching placebo
Drug: Pelacarsen (TQJ230) 80mg

This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure...

Begins enrollment in 1 month
Heart Failure
Drug: CDR132L
Drug: Placebo

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either...

Enrolling
Systemic Inflammation
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new invest...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Placebo

This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Active, not recruiting
Type 2 Diabetes
Drug: Placebo
Drug: Semaglutide

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Cagrilintide

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in partic...

Begins enrollment this month
Overweight
Obesity
Drug: Bimagrumab Placebo
Drug: Tirzepatide Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropath...

Enrolling
Diabetic Peripheral Neuropathy
Drug: LY3556050
Drug: Placebo
Locations recently updated

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo
Locations recently updated

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Active, not recruiting
Seasonal Influenza
Biological: Fluarix Tetra
Biological: Fluarix®

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

Trial sponsors

Lilly logo
Novo Nordisk logo
Merck Sharp & Dohme (MSD) logo
Boehringer Ingelheim logo
Novartis logo
AstraZeneca logo
Janssen (J&J Innovative Medicine) logo
N
Pfizer logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems